Sukumar Nagendran - 28 Nov 2025 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Role
President and Head of R&D, Director
Signature
/s/ Kamran Alam, Attorney-in-Fact
Issuer symbol
TSHA
Transactions as of
28 Nov 2025
Transactions value $
-$1,133,863
Form type
4
Filing time
01 Dec 2025, 20:58:44
Previous filing
12 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Nagendran Sukumar President and Head of R&D, Director C/O TAYSHA GENE THERAPIES, INC., 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS /s/ Kamran Alam, Attorney-in-Fact 01 Dec 2025 0001665124

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TSHA Common Stock Options Exercise $49K +70.2K +6.97% $0.70 1.08M 28 Nov 2025 Direct
transaction TSHA Common Stock Options Exercise $68.3K +40K +3.71% $1.71 1.12M 28 Nov 2025 Direct
transaction TSHA Common Stock Sale -$523K -110K -9.86% $4.75 1.01M 28 Nov 2025 Direct F1
transaction TSHA Common Stock Options Exercise $445K +260K +25.84% $1.71 1.27M 01 Dec 2025 Direct
transaction TSHA Common Stock Sale -$1.17M -260K -20.53% $4.51 1.01M 01 Dec 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TSHA Employee Stock Option (right to buy) Options Exercise $0 -70.2K -23.96% $0.00 223K 28 Nov 2025 Common Stock 70.2K $0.70 Direct F3
transaction TSHA Employee Stock Option (right to buy) Options Exercise $0 -40K -4.63% $0.00 824K 28 Nov 2025 Common Stock 40K $1.71 Direct F4
transaction TSHA Employee Stock Option (right to buy) Options Exercise $0 -260K -31.57% $0.00 564K 01 Dec 2025 Common Stock 260K $1.71 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.7248 to $4.8348 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2).
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.42 to $4.63 inclusive.
F3 The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date.
F4 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.